Applying Next-Generation Sequencing Technologies: Introduction to New Technologies and Application in Research DVD
About the DVD:
Technologies for next generation sequencing are accelerating at a rapid pace. This DVD will present up-to-date information on the newest options for DNA sequencing, and the tools to manage the data. The major new advantages will be showcased in the latest platforms, and strategies for managing the data to turn it into useful information will be demonstrated by leaders in the field.
• Technologies for newest platforms next generation sequencing
• Strategies and tools for managing data
• Demonstration of how tools can be applied to research
About the Conference:
The one scientific event for cutting-edge research, trends and analysis. The future holds great promise for molecular medicine, however the demand for results today is ever mounting, from both patients and businesses alike. The Molecular Med Tri-Con is the place to find the tools to turn ‘someday’ into ‘now’. ATTEND. DISCOVER. APPLY.
This DVD includes two bonus presentations including: “Deconstructing the Drug Development Process: The New Face of Innovation” and “To the $1,000 Genome — and Beyond”
Molecular Med TRI-CON 2011 – a LIFE changing event
About the DVD:
Over 138 Slides
Individual Copy: $345
Site License: $1380
Agenda At A Glance:
Targeted Sequencing and New Technologies
Instructor: Ronald W. Davis, Ph.D., Professor, Biochemistry & Genetics, and Director, Stanford Genome Technology Center, Stanford University
Biography: Ronald W. Davis, Ph.D., Professor, Biochemistry & Genetics, and Director, Stanford Genome Technology Center, Stanford University
Dr. Davis is currently a professor of biochemistry and genetics and director of the Stanford Genome Technology Center at Stanford University. His many honors include the 2005 Dickson Prize in Medicine, the University of Pittsburgh School of Medicine's most prestigious award; the Lifetime Achievement Award of the Genetics Society; the Herbert A. Sober Award; and the Genetics Society of America Award. After receiving his doctorate from Caltech, Davis held an NIH Postdoctoral Fellowship at Harvard University, then joined Stanford's department of biochemistry as an assistant professor in 1972. He became an associate professor in 1977, a professor in 1980, and a professor in the department of genetics in 1990. He was appointed director of the Stanford Genome Technology Center in 1994 and served in the senate of the Stanford University School of Medicine Faculty Council from 2000 to 2002.
Discovery of Biologics and Biomarkers in the Antibody Repertoire
Instructor: Jacob Glanville, Bioinformatics Analyst, Pfizer Global R&D
The adaptive immune system detects novel molecular surfaces with a vast repertoire of stochastically diversified antibody receptors. Assays to isolate selective binders have led to a proliferation of research reagents, antibody therapeutics and biological insights. This presentation will review some of the methods, challenges and opportunities in applying high throughput sequencing to the analysis of entire antibody repertoires and cover the following topics:
antibody screening analysis for biologic development
NGS analysis of phage display repertoires
NGS analysis of natural repertoires
Biography: Jacob Glanville earned a BA in molecular and cell biology at the University of California, Berkeley. "While there, a programming hobby and a Linux hobby turned into a work-related convenience," he says, when he joined a population genetics lab and started writing genomics software. "That's where I was until I was recruited by Giles to develop computational biology for the new BBC division" of Pfizer, he says. He brings to Pfizer his expertise with complex algorithms for sequence and structure analysis.
Agile Infrastructure in the Sequencing Era
Instructor: Adam Kraut, Scientific Consultant, BioTeam, Inc.
This presentation will highlight experiences and emerging best practices in IT infrastructure as it applies to Next-Gen Sequencing. We will introduce infrastructure as code, distributed data storage, and the role of cloud computing in building scalable application architectures. This course will cover the following topics:
Biography: Adam Kraut specializes in HPC and Cloud computing for the Life Sciences. Before joining Bioteam he was a researcher at the Pittsburgh Supercomputing Center and National Resource for Biomedical Supercomputing developing new methods for protein structure prediction and competing in multiple rounds of CASP. While at the PSC he also contributed to core projects in biomolecular simulation, enzyme design, and multi-scale modeling. In addition to high-performance computing support and software development, Kraut brings practical experience in structural bioinformatics and macromolecular modeling to Bioteam.
This DVD includes two bonus presentations including: “Deconstructing the Drug Development Process: The New Face of Innovation” delivered by Kenneth Kaitin, Ph.D., Director, Tufts Center for Study of Drug Development and “To the $1,000 Genome — and Beyond” delivered by Kevin Davies, Ph.D., Author, The $1,000 Genome; Editor-in-Chief, Bio-IT World. These two talks were presented as part of the Plenary Keynote at the Molecular Med Tri-Conference.
Deconstructing the Drug Development Process: The New Face of Innovation
Kenneth Kaitin, Ph.D., Director, Tufts Center for Study of Drug Development
For over 30 years, the Center for the Study of Drug Development at Tufts University has documented the increasing challenge of bringing new pharmaceutical products to market. To succeed in today’s competitive marketplace, research-based drug and biotech companies must not only maintain their focus on R&D efficiency and output, but they must also be able to adjust to a rapidly changing and highly volatile R&D environment. In this presentation, Dr. Kaitin will use Tufts CSDD data to document the current status of pharmaceutical R&D and explore new models of innovation.
To the $1,000 Genome — and Beyond
Kevin Davies, Ph.D., Author, The $1,000 Genome; Editor-in-Chief, Bio-IT World
The field of genome analysis has undergone a revolution in recent years. Next-generation sequencing technologies have dropped the cost of sequencing a human genome from about $1 million in 2007 to less than $10,000 in 2010, with new third- and fourth-generation technologies on the horizon. But will the arrival of the $1,000 genome have any meaningful impact on drug development and the practice of medicine? Kevin Davies, author of The $1,000 Genome will share his observations on the landmarks in next-generation sequencing. He will also highlight the challenges that remain in next-gen data generation, analysis and dissemination for the research and medical communities.